# LDB2

## Overview
LDB2, or LIM domain binding 2, is a gene that encodes the LIM domain binding protein 2, a crucial component in transcriptional regulation. This protein is categorized as a transcriptional co-regulator, which, despite lacking direct DNA binding capability, plays a significant role in modulating gene expression through its interactions with other proteins. LDB2 is involved in forming multimeric complexes with LIM-Homeodomain (LIMHD) and LIM-Only (LMO) proteins, facilitating its regulatory functions (Chu2023LIMdomain). The protein is implicated in various cellular processes, including the inhibition of oncogenic pathways in cancers such as hepatocellular carcinoma and lung cancer, where it acts as a tumor suppressor by interacting with chromatin remodelers and signaling pathways (Yu2017LDB2; Chu2023LIMdomain). Additionally, LDB2's role in the Wnt signaling pathway underscores its importance in cancer biology, making it a potential target for therapeutic interventions (Wang2023Structural).

## Clinical Significance
Alterations in the expression of the LDB2 gene have been implicated in various cancers. In colorectal cancer (CRC) and advanced adenomas (AA), LDB2 is part of a panel of serum methylation biomarkers used for early detection. The methylation of LDB2, along with other genes, has shown potential as a noninvasive biomarker for distinguishing between advanced neoplasia and non-neoplastic conditions, with models demonstrating high specificity and moderate sensitivity (GallardoGómez2023Serum). 

In hepatocellular carcinoma (HCC), LDB2 is downregulated, acting as a tumor suppressor. Its reduced expression is associated with increased proliferation and migration of liver cancer cells. LDB2 inhibits the oncogene HEY1 by recruiting BRD7 to the HEY1 promoter, and its deletion leads to enhanced tumor growth, suggesting its role in suppressing HCC progression (Yu2017LDB2).

LDB2 is also involved in the Wnt signaling pathway, where it forms part of the Wnt enhanceosome complex. This complex is crucial for the transcription of Wnt target genes, which are often mutated in cancers such as colorectal cancer. Disruption of LDB2 interactions within this complex can impair Wnt signaling, highlighting its significance in cancer biology (Wang2023Structural).

## Interactions
LIM domain binding protein 2 (LDB2) is involved in several protein interactions that influence its role as a transcriptional regulatory factor. In hepatocellular carcinoma (HCC), LDB2 interacts with BRD7, a chromatin remodeler, to inhibit the expression of the oncogene HEY1. This interaction occurs at the HEY1 promoter, where LDB2 recruits BRD7 to repress HEY1 transcription, thereby inhibiting tumor cell proliferation and migration (Yu2017LDB2).

In lung cancer, LDB2 is targeted by miR-96-5p, which downregulates its expression. This interaction affects the ERK1/2 signaling pathway, influencing cell proliferation, invasion, and metastasis. The miR-96-5p binds to the 3′-UTR of LDB2, promoting oncogenic behaviors in lung cancer cells (Chu2023LIMdomain).

LDB2 is also part of the LIM domain binding family, which forms multimeric complexes with LIM-Homeodomain (LIMHD) and LIM-Only (LMO) proteins. These interactions allow LDB2 to regulate transcription despite lacking direct DNA binding capacity (Chu2023LIMdomain). These interactions highlight LDB2's role in modulating gene expression and its potential as a therapeutic target in cancer.


## References


[1. (GallardoGómez2023Serum) María Gallardo-Gómez, Mar Rodríguez-Girondo, Núria Planell, Sebastian Moran, Luis Bujanda, Ane Etxart, Antoni Castells, Francesc Balaguer, Rodrigo Jover, Manel Esteller, Joaquín Cubiella, David Gómez-Cabrero, and Loretta De Chiara. Serum methylation of galnt9, upf3a, wars, and ldb2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas. Clinical Epigenetics, October 2023. URL: http://dx.doi.org/10.1186/s13148-023-01570-1, doi:10.1186/s13148-023-01570-1. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13148-023-01570-1)

[2. (Yu2017LDB2) Hongyang Yu, Ruichun Jia, Ling Zhao, Shigang Song, Jing Gu, and Haogang Zhang. Ldb2 inhibits proliferation and migration in liver cancer cells by abrogating hey1 expression. Oncotarget, 8(55):94440–94449, October 2017. URL: http://dx.doi.org/10.18632/oncotarget.21772, doi:10.18632/oncotarget.21772. This article has 10 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.21772)

[3. (Wang2023Structural) Hongyang Wang, Mariann Bienz, Xiao-Xue Yan, and Wenqing Xu. Structural basis of the interaction between bcl9-pygo and ldb-ssbp complexes in assembling the wnt enhanceosome. Nature Communications, June 2023. URL: http://dx.doi.org/10.1038/s41467-023-39439-9, doi:10.1038/s41467-023-39439-9. This article has 1 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-39439-9)

[4. (Chu2023LIMdomain) Fuying Chu, Xinxin Xu, Yan Zhang, Hua Cai, Jingjing Peng, Yanan Li, Han Zhang, Hongli Liu, and Xiang Chen. Lim-domain binding protein 2 was down-regulated by mirna-96-5p inhibited the proliferation, invasion and metastasis of lung cancer h1299 cells. Clinics, 78:100145, January 2023. URL: http://dx.doi.org/10.1016/j.clinsp.2022.100145, doi:10.1016/j.clinsp.2022.100145. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.clinsp.2022.100145)